Heron Therapeutics Files 2024 10-K
Ticker: HRTX · Form: 10-K · Filed: Feb 27, 2025 · CIK: 818033
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
TL;DR
Heron Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Heron Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as AP Pharma Inc. and Advanced Polymer Systems Inc., is based in San Diego, CA. The filing details its business operations in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Heron Therapeutics' financial performance, strategic initiatives, and risk factors for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Heron Therapeutics faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Numbers
- 20241231 — Fiscal Year End (The reporting period for the 10-K filing.)
- 20250227 — Filing Date (The date Heron Therapeutics submitted its 10-K.)
Key Players & Entities
- HERON THERAPEUTICS, INC. /DE/ (company) — Filer
- AP PHARMA INC /DE/ (company) — Former Company Name
- ADVANCED POLYMER SYSTEMS INC /DE/ (company) — Former Company Name
- 20241231 (date) — Fiscal Year End
- 20250227 (date) — Filing Date
- SAN DIEGO, CA (location) — Business Address
FAQ
What were Heron Therapeutics' primary revenue drivers in fiscal year 2024?
The 10-K filing would detail specific product revenues and any licensing or royalty income, but this summary does not contain that level of detail.
What are the key research and development activities Heron Therapeutics is pursuing?
The filing mentions 'ResearchAndDevelopmentExpense' but does not specify the particular drugs or therapeutic areas under development.
Did Heron Therapeutics announce any significant acquisitions or divestitures in 2024?
This filing is a 10-K for the fiscal year ending 2024 and does not explicitly mention acquisitions or divestitures in the provided header information.
What is Heron Therapeutics' current cash position as of December 31, 2024?
The provided header information does not include specific financial figures like cash on hand.
What are the main risks highlighted by Heron Therapeutics for the upcoming fiscal year?
While the filing is a 10-K, the specific risks are not detailed in the provided header information, though general pharmaceutical risks are implied.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding HERON THERAPEUTICS, INC. /DE/ (HRTX).